MMCAP/MM Asset report 8.0% stake in Akari Therapeutics (NASDAQ: AKTX)
Rhea-AI Filing Summary
Akari Therapeutics, Plc. ownership disclosure: MMCAP International Inc. SPC and MM Asset Management Inc. report beneficial ownership of 8,000,000,000 Ordinary Shares, representing 8.0% of the class. The position represents 100,000 American Depositary Shares, each convertible into 80,000 Ordinary Shares, with the percent calculated on a partially‑diluted basis using 91,567,009,533 Ordinary Shares outstanding as of March 31, 2026 per the issuer's 10-Q. Both filers report shared voting power of 8,000,000,000 and shared dispositive power of 8,000,000,000.
Positive
- None.
Negative
- None.
Insights
Large ADS-derived stake reported: 8.0% beneficial ownership via 100,000 ADS convertible into 8,000,000,000 Ordinary Shares.
The filing states that 100,000 ADS are each convertible into 80,000 Ordinary Shares, amounting to 8,000,000,000 Ordinary Shares and 8.0% on a partially‑diluted basis using March 31, 2026 outstanding shares. This describes the legal economic exposure held through ADSs rather than direct share issuance.
Cash‑flow treatment and trading intent are not disclosed in the excerpt; subsequent filings or public statements would be required to clarify whether the position is passive or seeks influence.
Shared voting and dispositive power reported for the two related filers; governance influence depends on coordination between entities.
The report lists shared voting power of 8,000,000,000 and shared dispositive power of 8,000,000,000 for both MMCAP International Inc. SPC and MM Asset Management Inc. The joint filing agreement is referenced via Exhibit 99.1 and signatures are provided.
Whether this stake translates into board influence or proposal power depends on future disclosures and any coordination described in additional filings.
Key Figures
Key Terms
partially-diluted basis regulatory
beneficially owned regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.